Revvity, Inc.

$ 100.00 2.23 %

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

CEO: Prahlad R. Singh - http://www.revvity.com

Price objectif

$109.83 9.83 %

Recommandation

Buy

DCF

$ 105.14

Loading data...

RVTY vs S&P500

Loading data...

No data available.

Quick ratio

1.41

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

48.08

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

2.08

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

3.28 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

2.89 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

7.91

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.47

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

4.41

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

13.37 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
7 indicates good financial health
Altman score
2.53 indicates an uncertain financial situation
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.69 indicates that the company has a moderate ability to cover its short-term debts with its cash
Debt Ratio
0.28 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.